Drugs / AVX101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00097838 | Oct 2004 → Sep 2009 | HIV infectious disease | AlphaVax, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00063778 | Jul 2003 → Jul 2005 | HIV infectious disease | AlphaVax, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00097838 ↗ |
| Modality | Vaccine | “an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101)” PMID 22914365 ↗ Aug 2012 |
| Route | Subcutaneous | “Escalating doses of AVX101 or placebo were administered subcutaneously” PMID 22914365 ↗ Aug 2012 |